The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWarpaint London Regulatory News (W7L)

Share Price Information for Warpaint London (W7L)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 472.50
Bid: 470.00
Ask: 475.00
Change: -12.50 (-2.58%)
Spread: 5.00 (1.064%)
Open: 485.00
High: 485.00
Low: 472.50
Prev. Close: 485.00
W7L Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Placing

13 Nov 2017 11:57

RNS Number : 3318W
Warpaint London PLC
13 November 2017
 

13 November 2017

 

Warpaint London PLC

("Warpaint", the "Company" or the "Group")

 

Results of Placing

 

Warpaint London PLC (AIM: W7L), the specialist supplier of colour cosmetics and owner of the W7 brand, is pleased to announce the successful completion of the Placing announced earlier today.

 

A total of 11,157,894 Placing Shares have been placed subject to shareholder approval being obtained at a general meeting of Shareholders to be convened for 29 November 2017. The Placing Shares will be allocated to Placees at a price of 190 pence per share, raising gross proceeds of £21.2 million. Subject to the General Meeting and Completion of the Acquisition which was also announced earlier today, settlement and admission to trading on AIM of the Placing Shares is expected to occur on 30 November 2017.

 

The Placing Shares will represent, in aggregate, approximately 15 per cent. of the issued ordinary share capital of the Company as enlarged by the issue of the Placing Shares and the Consideration Shares. The Placing Price represents a discount of 8 per cent. on the closing price on 10 November 2017, being the last practicable closing mid-market price prior to the announcement issued by the Company at 7.00 a.m. this morning.

 

The Company is today dispatching a circular containing a notice of general meeting at which resolutions will be put to the Shareholders to authorise the allotment of new ordinary shares on a non-pre-emptive basis to fulfil the Placing and the Acquisition.

 

 

Commenting, Sam Bazini and Eoin Macleod, Joint Chief Executives of Warpaint said: "We are delighted with the interest in the Placing we received. We would like to welcome our new shareholders and thank all of our existing shareholders for their on-going support."

 

 

Directors' participation

 

Directors of the Company have, in aggregate subscribed for 352,628 new Ordinary Shares (£669,993 at the Placing Price) in the Placing.

 

The participation of the Directors of the Company (and/or their connected persons) in the Placing is set out in the table below:

 

Beneficial holding before the Placing

Placing Shares

Beneficial holding following the Placing and the issue of the Consideration Shares

(shares)

(%)

(shares)

(shares)

(%)

Sam Bazini*

20,413,630

31.63%

 131,578

 20,545,208

26.77%

Eoin Macleod*

20,413,630

31.63%

 131,578

 20,545,208

26.77%

Clive Garston

100,000

0.15%

 26,315

 126,315

0.16%

Paul Hagon

20,619

0.03%

10,526

 31,145

0.04%

Neil Rodol

61,856

0.10%

42,105

 103,961

0.14%

Keith Sadler

20,619

0.03%

10,526

 31,145

0.04%

 

* Including 3,000,000 Ordinary Shares held by the Director's wife

 

General Meeting

 

The Company intends to today send a circular to Shareholders to convene a general meeting of Shareholders to be held at 9.30 a.m. on 29 November 2017 at the offices of DAC Beachcroft LLP, 100 Fetter Lane, London, EC4A 1BN.

 

The Placing is conditional, inter alia, upon the following:

 

· the passing, without amendment, of the Resolutions at the General Meeting;

 

· Admission occurring by no later than 8.00 a.m. on 30 November 2017 (or such later times and/or dates as may be agreed between the Company and Stockdale, being no later than 22 December 2017); and

 

· the Placing and the Acquisition becoming unconditional in all respects and not having been terminated in accordance with their terms.

 

If the conditions set out above are not satisfied or waived (where capable of waiver), the Placing will lapse and the Placing Shares will not be issued and all monies received from investors in respect of the Placing Shares will be returned to them (at the investors' risk and without interest) as soon as possible thereafter.

 

Capitalised terms used in this announcement but not defined herein shall have the meaning set out in the Definitions section of the announcement issued by the Company at 7.00 a.m. this morning.

 

-Ends-

 

Enquiries:

 

Warpaint London PLC

Sam Bazini - Joint Chief Executive Officer

Eoin Macleod - Joint Chief Executive Officer

Neil Rodol - Chief Financial Officer

 

020 3053 8671

 

Stockdale Securities Limited (Nominated Adviser and Broker)

Mark Brown, Antonio Bossi, Ed Thomas - Corporate Finance

Fiona Conroy - Corporate Broking

 

020 7601 6100

 

IFC Advisory Limited (Financial PR & IR)

Tim Metcalfe

Graham Herring

Heather Armstrong

Miles Nolan

020 3053 8671

 

 

About Warpaint London PLC

 

Warpaint London is a colour cosmetics business, based in Iver, Buckinghamshire. It is made up of two divisions: close-out and own-brand. The second and larger own-brand division consists primarily of the Group's flagship brand, W7 - an extremely creative, design-focused cosmetic brand proposition with a focus on the 16-30 age range, delivering high-quality cosmetics at affordable prices. The W7 brand has grown organically since its inception in 2002 and now contains over 500 items which are sold into high street retailers and independent beauty shops across the UK, Europe, Australia and the US. In 2016, W7 was supplied to over 250 customers in more than 50 countries.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEKMMMMMFDGNZM
Date   Source Headline
24th Apr 20247:00 amRNSResults for the year ended 31 December 2023
9th Apr 20247:00 amRNSBlock listing Interim Return
9th Apr 20247:00 amRNSTrading Update and Notice of Results
26th Mar 20242:37 pmRNSHolding(s) in Company
1st Feb 20247:00 amRNSWard & Hagon Contract Renewal
12th Jan 20247:00 amRNSTrading Update
12th Dec 20237:00 amRNSAppointment of Non-Executive Directors
1st Dec 20233:37 pmRNSTotal Voting Rights
24th Nov 20237:00 amRNSGrant of Options
21st Nov 202311:23 amRNSPDMR Dealing
20th Nov 20231:24 pmRNSHolding(s) in Company
10th Nov 20237:00 amRNSTrading Update
9th Nov 20237:00 amRNSBlock Listing Interim Return
31st Oct 20237:00 amRNSTotal Voting Rights
13th Oct 20233:38 pmRNSHolding(s) in Company
4th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20233:26 pmRNSHolding(s) in Company
3rd Oct 202312:25 pmRNSBlocklisting Application
28th Sep 20235:47 pmRNSHolding(s) in Company
20th Sep 20237:00 amRNSInterim Results
19th Sep 20233:51 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
22nd Aug 202312:31 pmRNSHolding(s) in Company
27th Jul 20234:34 pmRNSHolding(s) in Company
3rd Jul 20237:00 amRNSTotal Voting Rights
28th Jun 20231:40 pmRNSResult of AGM
28th Jun 20237:00 amRNSAGM Statement
15th Jun 20237:00 amRNSTrading Update
6th Jun 20237:00 amRNSPDMR Dealings
24th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
9th May 202311:28 amRNSHolding(s) in Company
2nd May 20234:31 pmRNSBlocklisting Application
26th Apr 20237:00 amRNSResults for the year ended 31 December 2022
24th Mar 20237:00 amRNSTrading Update and Notice of Results
14th Feb 202310:16 amRNSAIM Rule 17 Notification
11th Jan 20237:00 amRNSFull Year Trading Update
3rd Jan 20237:00 amRNSResignation of Non-Executive Director
14th Oct 20227:00 amRNSRenewal of New Moorcroft House lease at Silsden
21st Sep 20227:00 amRNSInterim Results
16th Sep 20227:00 amRNSChange of Adviser
8th Sep 20224:40 pmRNSSecond Price Monitoring Extn
8th Sep 20224:36 pmRNSPrice Monitoring Extension
8th Sep 20222:06 pmRNSSecond Price Monitoring Extn
8th Sep 20222:00 pmRNSPrice Monitoring Extension
8th Sep 202211:05 amRNSSecond Price Monitoring Extn
8th Sep 202211:00 amRNSPrice Monitoring Extension
8th Sep 20227:00 amRNSTrading Update
1st Sep 20227:00 amRNSNotice of Results and Investor Webinar
29th Jun 20227:00 amRNSPMDR / PCA Dealing
28th Jun 20227:00 amRNSDirector/PDMR Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.